A groundbreaking Dutch study has identified a key mechanism behind prostate cancer cells' resistance to anti-hormonal therapies, potentially accelerating treatment advancements by a decade.
Prostate cancer, a common malignancy in the male reproductive system, thrives on excessive androgen hormone production. Anti-hormonal therapies aim to curb this by lowering hormone levels, effectively slowing disease progression in many patients. However, resistance often develops. Researchers at the Netherlands Cancer Institute, publishing in Cancer Discovery on June 27, 2022, unveiled an “unexpected potential solution”.
Rather than directly attacking cancer cells, this approach targets specific proteins. The team discovered a class of proteins that regulate circadian rhythms in healthy cells. Prostate cancer cells lose their circadian rhythm, but under hormone therapy, these proteins take on a new role, enabling cancer cells to survive treatment.
Analyzing tissue from 56 patients with advanced prostate cancer after three months of anti-hormonal treatment, the study found that genes sustaining tumor cells were now controlled by these circadian clock proteins. Collaborating with the Dutch Oncode Institute, researchers are developing strategies to block this process, thereby boosting therapy effectiveness.
This insight encourages innovative approaches, such as testing drugs that target circadian clock proteins. By repurposing existing therapies, this could streamline development and save a decade of research.
